Berzosertib – Trial Rational
Berzosertib is the first to be studied of a new family of treatments. These drugs block a protein involved in DNA repair, “ATR kinase”. Blocking this protein prevents cancers from mending damage to their cells.
Berzosertib is able to target cancer cells without affecting other healthy cells.
M6620 (Berzosertib) First in Human Study was what is known as a “Phase I” trial. Phase I trial is only designed to test the safety of a treatment.
Berzosertib was administered in combination with chemotherapy or as monotherapy.
Participants enrolled had metastatic or unresectable cancer and for which standard treatments do not exist or are no longer effective.
More than half of the 40 patients given Berzosertib alone had the growth of their cancers halted.
Berzosertib was even more effective when given alongside chemotherapy.
Further trials will be needed to demonstrate the drug’s effectiveness, though.
“I was told ‘there’s nothing more we can do for you’,” he said. “In April 2014, I was told ‘you’ll probably be dead by Christmas'”.
He has now been receiving Berzosertib treatment for six years, his cancers have shrunk and his condition is stable.
Another patient, whose ovarian cancer returned, saw her cancers shrink after combination treatment.
Berzosertib was well tolerated. The most common side effects included flushing, nausea, pruritus, headache and infusion-related reactions.
The next phase of studying Berzosertib in clinical trials is already under way.
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039